Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
The neuronal nicotinic acetylcholine receptor subunit alpha-3 and beta-4 (α3β4 nicotinic receptor) forms heteropentameric ligand-gated cation channels highly expressed in autonomic ganglia and the habenulo-interpeduncular tract, where it mediates excitatory synaptic transmission through high calcium permeability and cation influx upon acetylcholine or nicotine binding. These receptors assemble with stoichiometries such as (α3)m(β4)n where m+n=5, often incorporating accessory subunits like α5, and exhibit distinct kinetics including slower inactivation compared to other subtypes like α4β2. In the autonomic nervous system, α3β4 receptors serve as the principal relay between central and peripheral neurons, regulating functions like smooth muscle contraction and neurotransmitter release. They also modulate mesolimbic dopamine pathways in reward circuits, contributing to behaviors such as drug-seeking and addiction vulnerability. Antagonists targeting α3β4 show promise as anti-addictive agents by attenuating nicotine reinforcement without broadly impacting other nicotinic receptors. Structural studies reveal agonist binding at α-β subunit interfaces, with lipid environments influencing conductance and selectivity. Therapeutic challenges include balancing efficacy against potential autonomic side effects from ganglionic blockade.
Ligand-gated cation channel activation leading to increased Na+ and K+ permeability and postsynaptic excitation, Antagonism to inhibit receptor activity and modulate drug-seeking behavior
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Neuronal nicotinic acetylcholine receptor subunit alpha-3 and beta-4 (α3β4 nicotinic receptor).